Life Science Nation Newsletter  |  November 13, 2014  |  Issue 88

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Nov. 5 - Nov. 12)

Looking Opportunistically in Life Science, with Special Interest in Regenerative Medicine

Seeking to Invest in Healthcare IT an Imaging Technologies

Looking Globally for Revolutionary Life Science Opportunities
In This Issue

Looking For Capital? The Top Three Questions For Fundraising CEOs Before You Start

Asia and Israel in the Hunt for Cardiovascular Innovation 


RESI Early Stage Medtech Investor Panel Announced


LSN Videos
RESI 2014 Fall, Fenway Park
RESI 3 Family Office Panel
RESI 3 Outbound Fundraising Panel 
RESI 3 Corporate Venture Capital Panel
The Life Science Executive's Fundraising Manifesto
Looking For Capital? The Top Three Questions For Fundraising CEOs Before You Start

By Dennis Ford, Founder & CEO, LSN 


At LSN, my five business development executives talk to about 35 CEOs each week, all of whom are in fundraising mode.  If we also consider the conferences and seminars we attend, LSN's business development staff has spoken to close to a thousand fundraising executives since the company was founded.  Now, that is not a bad sample size.  At LSN, we always begin with three questions that will help us net out the status of the entrepreneurs we are starting a dialogue with.

The first question is, "Are you indeed fundraising?"  One would think this question is a binary matter...but it's not.  The answers range from "Yes, we're totally dedicated to raising money," to "We are just sticking with our private network of investors," to "We plan on starting a campaign soon." What these answers reveal is how committed you are to raising capital, and that's why it's the most important question for us; LSN engages only with dedicated fundraisers...


Asia and Israel in the Hunt for Cardiovascular Innovation 
By Michael Quigley, Director of Research, LSN


Cardiovascular disease, the leading cause of death in the U.S., represents a massive market for life science products. LSN's tracks both companies working on new technologies in the cardio space as well as investors looking to fund those technologies through our two data platforms. Looking at both companies and investors can provide a dynamic picture of the space as a whole.

Of the cardio technologies currently in development or in clinical trials worldwide, LSN has identified 561 that are therapeutic and diagnostic products and 238 that are medical devices. We then looked at cardio sub-indications to determine which ones have the most new-product development. (See Figure 1.)...




RESI Early Stage Medtech Investor Panel Announced

By Tom Crosby, RESI Conference Manager, LSN 


Last week, LSN announced the RESI Conference's new Commercializing Medtech Innovation panel, which will bring insights from investors who focus on devices that are nearing commercialization. This week, LSN is proud to announce another brand new panel in the Medtech Investor Panels track - this time, featuring investors who focus on earlier-stage opportunities. The In Development / Clinical Investors Medtech panel will offer viewpoints and advice from a diverse group of investors.


Moderated by Vicki Anastasi, Vice President & Global Head of Medical Device and Diagnostic Research at ICON, the audience will hear from:

  • Cary Adams, Founder, Almond Tree Capital
  • Jeff Sheldon, Managing Director, CitareTX
  • Ibraheem Badejo, Senior Director, New Ventures, Johnson & Johnson Innovation
  • Doug Fisher, Partner, InterWest Partners

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668


follow us: Follow us on Twitter View our profile on LinkedIn  

Michael Quigley, Director of Research, LSN
Nono Hu, Senior Manager, Branding & Messaging, LSN